摘要
以PD-1/PD-L1抑制剂为代表的免疫治疗已成为恶性肿瘤的主要治疗方法。然而,免疫治疗带来的不良反应也不容忽视。其中,皮肤免疫相关不良事件(irAE)最为常见,绝大多数的皮肤irAE属于Ⅰ~Ⅱ级,并不影响PD-1/PD-L1抑制剂的应用。其发病机制尚未完全明了,最常见的类型为皮疹、瘙痒及白癜风,而国产PD-1抑制剂卡瑞利珠单抗特有的不良反应为反应性皮肤毛细血管增生症(RCCEP)。临床发现,在恶性黑色素瘤与非小细胞肺癌中,皮肤irAE可预测PD-1/PD-L1抑制剂的临床疗效,特别是RCCEP可作为预测卡瑞利珠单抗治疗非小细胞肺癌、肝癌及食管癌的疗效预测指标。
Immunotherapy represented by PD-1/PD-L1 inhibitors has become the main treatment of malignant tumors.However,the adverse events caused by immunotherapy can not be ignored.Among them,dermatological immune-related adverse events(irAEs)occur with the highest incidence.Most dermatological irAEs belong to gradeⅠ-Ⅱ,which does not affect the application of PD-1/PD-L1 inhibitors.The pathogenesis of dermatological irAEs is not fully understood.The most common types of dermatological irAEs are rash,pruritus and vitiligo.The domestic PD-1 inhibitor camrelizumab has unique adverse reactions of reactive cutaneous capillary endothelia proliferation(RCCEP).It is found that dermatological irAEs can predict the clinical efficacy of PD-1/PD-L1 inhibitors in patients with malignant melanoma and non-small cell lung cancer(NSCLC),especially RCCEP can be used as a potential biomarker of the efficacy of camrelizumab in the treatment of NSCLC,hepatocarcinoma,and esophageal cancer.
作者
丁心静
丁江华
Ding Xinjing;Ding Jianghua(First Clinical Medical College,Nanchang University,Nanchang 330006,China;Departmentof Oncology,Affiliated Hospital of Jiujiang University,Jiujiang 332000,China)
出处
《国际肿瘤学杂志》
CAS
2022年第4期225-228,共4页
Journal of International Oncology
作者简介
通讯作者:丁江华,E-mail:doctor0922@126.com。
